CURE2d
Padcev With or Without Keytruda Elicits Responses in Urothelial Cancer
In metastatic urothelial carcinoma, Padcev plus Keytruda elicited responses in the first-line setting, with Padcev showing ...
Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding ...
Personalized Cancer Vaccine Proves Promising in a Phase 1 Trial at Mount Sinai
A multi-peptide neoantigen cancer vaccine using relatively few antigens induced a strong immune response across multiple ...
Healio2d
Urine test may aid detection of high-grade invasive bladder cancer
A urinary DNA methylation test showed potential for detecting high-grade or invasive bladder cancer, according to results of ...
Conquering fear was key for Oak Forest man who overcame double cancer diagnosis
Fear is the worst thing against you,” said William Brtis, who was diagnosed with two different cancers six days apart.
Pfizer Is Trading As If It's 2009 Again
Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...
Bladder cancer link with explosive ordnance exposure among Army veteran bomb disposal officers
Survey suggests bladder cancer incidence around five times higher for veterans under 70 compared to the general public ...
Junshi Biosciences Announces Toripalimab's Approval in Singapore
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery ...
TMCnet1d
Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.
NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer (NMIBC, U.S. prevalence of ~600,000 ...